• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CP1
Click for more information
0.00% 17.0¢

CANNPAL ANIMAL THERAPEUTICS LIMITED - Corporate Spotlight

Currently unlisted. Proposed listing date: TBA watchlist Created with Sketch. Add to my watchlist

CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The... CannPal Animal Therapeutics Limited is an Australia-based pet pharmaceutical company. The Company is focused on research, developing and commercializing therapeutics for the companion animal health industry, using the compounds derived from the cannabis plants. It is focused on cats and dogs. Its lead drug candidate is CPAT-01, which targets osteosarcoma pain in dogs. It is also engaged in investigating and researching the ability to use cannabidiol derived from the hemp plant for developing a nutraceutical range of products for use in companion animals, including dogs, cats, birds, horses and other domestic animals, without a prescription. It is also developing pharmaceutical therapeutics for chronic pain and appetite stimulation. It is developing nutraceutical products for skin conditions, joint health and digestive health.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

No Corporate Spotlight currently available.

Top Stories

Lithium Universe reveals plan to fill a 'gap' in the North American market

Lithium Universe has flagged its Québec Lithium Processing Hub in Canada as a key producer of battery-grade lithium to the North American market..
Regal copper grades at Gascoyne play see shares jump 33% for Augustus Augustus Minerals is reporting high grade copper rock chip results at Ti-Tree in WA based on recent fieldwork.
Raiden’s jump into lithium territory in WA’s Pilbara echoes earlier journey by Azure In its bid to define a noteworthy lithium deposit in WA’s Pilbara region, Raiden Resources is following in the footsteps of another explorer.
Recce Pharmaceuticals up 6% on new antibiotic production milestone Recce Pharmaceuticals (ASX:RCE) is trading up more than 6 per cent after producing a 5000-dose batch of its new antibiotic RECCE 327 (R327) under Good Manufacturing Practises (GMP) standards.
BHP confirms £31.1B takeover bid for Anglo American BHP HAS confirmed its offer to takeover fellow mining giant Anglo American plc, following press speculation of a potential deal.which had unsettled shareholder groups and financial firms in London, and provoked criticism from a South African government minister.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.